Premium
Stratification of treatment intensity in relapsed pediatric Hodgkin lymphoma
Author(s) -
HarkerMurray Paul D.,
Drachtman Richard A.,
Hodgson David C.,
Chauvenet Allen Russell,
Kelly Kara M.,
Cole Peter David
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24851
Subject(s) - medicine , lymphoma , oncology , hodgkin lymphoma , chemotherapy , risk stratification , regimen , refractory (planetary science) , hematopoietic stem cell transplantation , radiation therapy , transplantation , physics , astrobiology
Risk‐adapted, response‐based therapies for pediatric Hodgkin lymphoma have resulted in 5‐year survival exceeding 90%. Although high‐dose chemotherapy and autologous hematopoietic stem cell transplantation (AHSCT) are considered standard for most patients with relapsed or refractory Hodgkin lymphoma, a subset of children with low risk relapse do not require AHSCT for cure. Currently there are no widely accepted criteria defining who should receive standard dose chemotherapy and/or radiotherapy, nor is there a standardized treatment regimen. We propose a risk‐stratified, response‐based algorithm for children with relapsed or refractory Hodgkin lymphoma that is based on a critical appraisal of published outcomes and prognostic factors. Pediatr Blood Cancer 2014;61:579–586. © 2013 Wiley Periodicals, Inc.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom